BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
296 hedge funds and large institutions have $9.26B invested in bluebird bio in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 96 increasing their positions, 97 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.3% less ownership
Funds ownership: 8.51% → 8.21% (-0.3%)
1% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 97
Holders
296
Holding in Top 10
3
Calls
$256M
Puts
$170M
Top Buyers
| 1 | +$113M | |
| 2 | +$93.1M | |
| 3 | +$79.7M | |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$75.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.8M |
Top Sellers
| 1 | -$232M | |
| 2 | -$53.9M | |
| 3 | -$31.5M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$30M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$27.9M |